Stocks · News reference
Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile
Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations.
Why Is Contineum Therapeutics Stock Falling Monday?
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.
Bristol-Myers Squibb shares are trading higher after the company announced results from unit RayzeBio's ACTION-1 trial of RYZ101, which study met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival with consistent safety results.